A Phase 1 interventional study of CKD-382(formulation I) and CKD-382(formulation II) in GERD, sponsored by Chong Kun Dang Pharmaceutical. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-11.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.
Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 27th largest by planned enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2020, is one of 21 in phase 1, and was the 45th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19+
Incheon St.Mary's Hospital · Sites in Korea, Republic of
Ages 19+
Jeil Pharmaceutical Co., Ltd. · Sites in Korea, Republic of
Ages 19+
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19–75
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 19 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 6 · Phase 3 11 · Phase 4 8
First in 2006; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 54 across the 52 interventional studies, 2,000 across the 19 observational. Of the 51 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 71 have an industry lead sponsor. The 10 most frequent:
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
Chong Kun Dang Pharmaceutical has 9 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
1 of the studies in Gastroesophageal Reflux with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07678177HK inno.N CorporationAn Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare pharmacokinetics, pharmacodynamics and safety after single/multiple administration of CKD-382 and D026 in healthy subjects
A randomized, open-label, crossover phase 1 clinical trial to compare pharmacokinetics, pharmacodynamics and safety after single / multiple administration of CKD-382 and D026 in healthy subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Test drug(CKD-382 formulation I) Period 2: Test drug(CKD-382 formulation II) Period 3: Reference drug(D026)
Drug: CKD-382(formulation I) · Drug: CKD-382(formulation II) · Drug: D026
Period 1: Test drug(CKD-382 formulation II) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation I)
Drug: CKD-382(formulation I) · Drug: CKD-382(formulation II) · Drug: D026
Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation I) Period 3: Test drug(CKD-382 formulation II)
Drug: CKD-382(formulation I) · Drug: CKD-382(formulation II) · Drug: D026
Period 1: Test drug(CKD-382 formulation I) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation II)
Drug: CKD-382(formulation I) · Drug: CKD-382(formulation II) · Drug: D026
Period 1: Test drug(CKD-382 formulation II) Period 2: Test drug(CKD-382 formulation I) Period 3: Reference drug(D026)
Drug: CKD-382(formulation I) · Drug: CKD-382(formulation II) · Drug: D026
Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation II) Period 3: Test drug(CKD-382 formulation I)
Drug: CKD-382(formulation I) · Drug: CKD-382(formulation II) · Drug: D026
1 tablet administered under fasting condition for 7days
1 tablet administered under fasting condition for 7days
1 tablet administered under fasting condition for 7days
AUCtau,ss(Area under the plasma drug concentration-time curve within a dosing interval at steady state) Evaluation PK after multiple dose
Time frame: 0~24h
Percent decrease from baseline in integrated gastric acidity for 24-hour interval after 7th dose Evaluation PD for ambulatory 24hr pH monitor
Time frame: Baseline versus Multiple dose during 7 days
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2020 (actual). Primary completion is estimated for Sep 2021, 12 months after the start.
Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's planned 12 months is above that.
Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chong Kun Dang Pharmaceutical →